POLIVY: payments to doctors
Payments that named POLIVY as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $4.4M
- Providers
- 7,149
- Transactions
- 19,687
- Average per transaction
- $225
The per-transaction average — $225 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 7,149 providers the average total is $621, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genentech, Inc. | $2,421,341 | 54.6% |
| Genentech USA, Inc. | $1,962,801 | 44.2% |
| F. Hoffmann-la Roche AG | $38,882 | 0.9% |
| Hoffmann-la Roche Limited | $14,633 | 0.3% |